NEW YORK, Oct 31 –Pharmacogenomics technology company Variagenics of Cambridge, Mass., said Tuesday strong revenue growth helped to the company to narrow its third quarter net losses to $6.4 million, or 35 cents a share, compared with losses of $6.6 million, or $10.75 a share a year ago.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.